SensAwake™ Sleep Quality Trial
SASQT
SASQT: SensAwake™ Sleep Quality Trial A Study to Test the Efficacy of the SensAwake™ Modification to Automatically Titrating Continuous Positive Airway Pressure to Reduce Wake After Sleep Onset in Patients With Moderate to Severe Obstructive Sleep Apnea.
1 other identifier
interventional
45
1 country
1
Brief Summary
The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep. This study will investigate Obstructive Sleep Apnea (OSA) and a automatically Adjusting Positive Airway Pressure (APAP) device with new technology called SensAwake™. This requires experimental confirmation in a randomised controlled trial. Double-blind randomised crossover trial comparing WASO on standard APAP with WASO using APAP modified by the addition of the SensAwake™ modification on consecutive nights in participants with moderate-to-severe OSA. A total number of 45 participants will be recruited from an OSA population, aged 18-65. Participants will consist of male and female patients diagnosed with moderate-severe OSA (Apnea Hypopnea Index (AHI) greater than or equal to 15 per hour. Eligible participants, according to the protocol approved by the HREC, providing written informed consent will be enrolled into the study. Patients will be enrolled sequentially according to the randomisation list. Patients will be randomised to APAP or APAP with the addition of the SensAwake™ modification. The investigator and study staff will be blinded to the treatment of any participant.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_4
Started Oct 2008
Shorter than P25 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2008
CompletedFirst Submitted
Initial submission to the registry
December 16, 2008
CompletedFirst Posted
Study publicly available on registry
December 18, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2009
CompletedJuly 12, 2011
July 1, 2011
7 months
December 16, 2008
July 10, 2011
Conditions
Outcome Measures
Primary Outcomes (1)
Change in Wake After Sleep Onset (WASO) between treatment with standard APAP and APAP modified by the addition of the SensAwake™ modification
1 Night
Secondary Outcomes (2)
Sleep Efficiency
1 night
Percentage of Slow Wave Sleep
1 night
Study Arms (2)
1
EXPERIMENTALAuto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
2
ACTIVE COMPARATORAuto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
Interventions
Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
Eligibility Criteria
You may qualify if:
- Aged 18-65 years with moderate-to-severe OSA (Apnea Hypopnea index equal to or greater than 15 per hour).
- Epworth Sleepiness Scale (ESS) scores 0-15 inclusive (normal to moderately severe daytime sleepiness).
- Fluency in both written and spoken English.
- Do not have unstable psychiatric disease.
- No other significant sleep disorder.
You may not qualify if:
- Participants prescribed and fitted with any PAP device in the past 2 years.
- Unstable cardiovascular disease (untreated or resistant hypertension acceptable).
- Inability to tolerate CPAP due to nasal obstruction or claustrophobia as determined by the study investigator.
- Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as psychiatric disease, history of non compliance to medical regimens, or unwillingness to comply with study requirements.
- Participation in another clinical trial in the previous month.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Woolcock Institute of Medical Research
Sydney, New South Wales, 2037, Australia
Related Publications (1)
Dungan GC 2nd, Marshall NS, Hoyos CM, Yee BJ, Grunstein RR. A randomized crossover trial of the effect of a novel method of pressure control (SensAwake) in automatic continuous positive airway pressure therapy to treat sleep disordered breathing. J Clin Sleep Med. 2011 Jun 15;7(3):261-7. doi: 10.5664/JCSM.1066.
PMID: 21677895DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Brendon Yee, MBChB
Woolcock Institute of Medical Research
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
December 16, 2008
First Posted
December 18, 2008
Study Start
October 1, 2008
Primary Completion
May 1, 2009
Study Completion
August 1, 2009
Last Updated
July 12, 2011
Record last verified: 2011-07